Skip to content
10-Q

Quarterly Report

Inmune Bio, Inc. INMB

0001213900-26-053338

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 26.59M sh
Shares Diluted Q1 2026 · Mar 31, 2026 26.59M sh
Shares Diluted Q1 2026 · Mar 31, 2025 22.5M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$3.4M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$6.82M
Stockholders Equity Q1 2026 · Mar 31, 2026 $19.62M
Stockholders Equity Q1 2026 · Dec 31, 2025 $23.52M
Stockholders Equity Q1 2026 · Mar 31, 2025 $29.67M
Stockholders Equity Q1 2026 · Dec 31, 2024 $32.1M
Current Liabilities Q1 2026 · Mar 31, 2026 $5.39M
Current Liabilities Q1 2026 · Dec 31, 2025 $8.42M
Total Liabilities Q1 2026 · Mar 31, 2026 $6.19M
Total Liabilities Q1 2026 · Dec 31, 2025 $8.83M
Current Assets Q1 2026 · Mar 31, 2026 $22.82M
Current Assets Q1 2026 · Dec 31, 2025 $29.89M
Total Assets Q1 2026 · Mar 31, 2026 $25.82M
Total Assets Q1 2026 · Dec 31, 2025 $32.35M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.20
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.43
Eps Basic Q1 2026 · Mar 31, 2026 −$0.20
Eps Basic Q1 2026 · Mar 31, 2025 −$0.43
Sga Expense Q1 2026 · Mar 31, 2026 $2.17M
Sga Expense Q1 2026 · Mar 31, 2025 $2.32M
Rd Expense Q1 2026 · Mar 31, 2026 $3.64M
Rd Expense Q1 2026 · Mar 31, 2025 $7.64M
Net Income Q1 2026 · Mar 31, 2026 −$5.41M
Net Income Q1 2026 · Mar 31, 2025 −$9.74M
Operating Income Q1 2026 · Mar 31, 2026 −$5.81M
Operating Income Q1 2026 · Mar 31, 2025 −$9.91M
Revenue Q1 2026 · Mar 31, 2025 $50K